Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Completed · Phase 1
Conditions studied: Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
In brief
The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).
Key facts
- Study ID
- NCT01088048
- Run by
- Gilead Sciences
- People needed
- 241
- Starts
- 2010-03-25
- Expected to finish
- 2015-04-28
- Last updated by the study team
- 2021-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clearview Cancer Institute — Huntsville, Alabama, United States
- UCLA — Los Angeles, California, United States
- Stanford Cancer Center — Palo Alto, California, United States
- Center for Cancer and Blood Disorders — Bethesda, Maryland, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Long Island Jewish Medical Center — New Hyde Park, New York, United States
- Weill Medical College of Cornell — New York, New York, United States
- Willamette Valley Cancer Institute and Research Center — Springfield, Oregon, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- MD Anderson Cancer — Houston, Texas, United States
- North Star Lodge Cancer Center — Yakima, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.